Literature DB >> 23198752

A systematic review of reference pricing: implications for US prescription drug spending.

Joy Li-Yueh Lee1, Micahel A Fischer, William H Shrank, Jennifer M Polinski, Niteesh K Choudhry.   

Abstract

Given rising pharmaceutical expenditures and the widespread use of reference pricing as a costcontainment instrument abroad, we systematically reviewed the evidence evaluating reference pricing policies. We performed a structured electronic search of peer-reviewed journals for studies published before that reported on the effects of reference pricing policies on medication use, payer and patient spending, and resource consumption. Our search yielded 16 studies describing 9 reference-pricing policies from 6 countries. Reference-pricing policies led to decreases in drug prices and increases in utilization of targeted medications, while also reducing payer and patient expenditures. In addition, these policies did not lead to increased use of medical services, such as physician office visits and hospitalization. These results suggest that reference pricing may be an attractive policy strategy for the US healthcare system.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23198752

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  11 in total

Review 1.  The relevance of systematic reviews on pharmaceutical policy to low- and middle-income countries.

Authors:  Andrew Lofts Gray; Fatima Suleman
Journal:  Int J Clin Pharm       Date:  2015-07-17

2.  Policies to improve access to pharmaceutical products in shortage: the experience of Iran food and drug administration.

Authors:  Nazila Yousefi; Najmeh Moradi; Rassoul Dinarvand; Golbarg Ghiasi; Hamidreza Inanloo; Farzad Peiravian
Journal:  Daru       Date:  2019-03-23       Impact factor: 3.117

3.  Reference pricing may have limited use but is not a blanket solution for laboratory testing.

Authors:  Robert L Schmidt; Peter E Jensen
Journal:  Ann Transl Med       Date:  2016-11

Review 4.  A conceptual framework for investigating the impacts of international trade and investment agreements on noncommunicable disease risk factors.

Authors:  Ashley Schram; Arne Ruckert; J Anthony VanDuzer; Sharon Friel; Deborah Gleeson; Anne-Marie Thow; David Stuckler; Ronald Labonte
Journal:  Health Policy Plan       Date:  2018-01-01       Impact factor: 3.344

5.  Association of Reference Pricing with Drug Selection and Spending.

Authors:  James C Robinson; Christopher M Whaley; Timothy T Brown
Journal:  N Engl J Med       Date:  2017-08-17       Impact factor: 91.245

6.  Consumer Choice Between Hospital-Based and Freestanding Facilities for Arthroscopy: Impact on Prices, Spending, and Surgical Complications.

Authors:  James C Robinson; Timothy T Brown; Christopher Whaley; Kevin J Bozic
Journal:  J Bone Joint Surg Am       Date:  2015-09-16       Impact factor: 5.284

7.  Impact of a commercial accountable care organization on prescription drugs.

Authors:  Hui Zhang; David W Cowling; Joanne M Graham; Erik Taylor
Journal:  Health Serv Res       Date:  2021-01-28       Impact factor: 3.734

8.  Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.

Authors:  N Maniadakis; G Kourlaba; J Shen; A Holtorf
Journal:  BMC Health Serv Res       Date:  2017-05-25       Impact factor: 2.655

9.  Moving towards a better path? A mixed-method examination of China's reforms to remedy medical corruption from pharmaceutical firms.

Authors:  Jianwei Shi; Rui Liu; Hua Jiang; Chunxu Wang; Yue Xiao; Nana Liu; Zhaoxin Wang; Leiyu Shi
Journal:  BMJ Open       Date:  2018-02-08       Impact factor: 2.692

10.  Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.

Authors:  Olivier J Wouters; Panos G Kanavos; Martin McKEE
Journal:  Milbank Q       Date:  2017-09       Impact factor: 4.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.